

RECEIVED  
CENTRAL FAX CENTER

JUL 12 2005

Serial No. 10/081,922  
Express Mail Label No. ER 485041242 US  
Atty Docket No. RGT 9771

**AMENDMENTS TO THE CLAIMS**

Please amend the Claims as follows.

Claims 1-22 (Cancelled)

23. (Twice Amended) A method of transfecting antigen presenting cells, the steps comprising selecting a gene delivery complex comprising DNA and a compound selected from the group consisting of sugars, polyethylenimine, and polyethylenimine derivatives and mixtures thereof, and applying the complex to the skin or mucosa surfaces of an animal, wherein said DNA comprises a nucleic acid sequence encoding at least one immunogenic protein operatively linked to a promoter, ~~wherein the immunogenic protein is from a lentivirus.~~

24. (Previously presented) The method of Claim 23, wherein the compound is selected from the group consisting of glucose and polyethylenimine derivatives.

25. (Twice Amended) The method of Claim 24, wherein the ~~polyethylenimine~~ polyethyleneimine derivative targets a the mannose receptor found on the surface of antigen presenting cells.

26. (Previously presented) The method of Claim 25, wherein the derivative is mannosylated polyethylenimine.

27. (Cancelled).

28. (Previously presented) The method of Claim 23, wherein the complex is electrostatically neutral.

29. (Cancelled)

30. (Twice Amended) The method of Claim 298, wherein the complex comprises a 5:1 ~~molar equivalent~~ ratio of polyethylenimine derivative ~~amine nitrogen per molar equivalent of~~ DNA phosphate.

31. (Previously presented) The method of Claim 23, wherein the gene delivery complex is formulated in a glucose solution.

Serial No. 10/081,922  
Express Mail Label No. ER 485041242 US  
Atty Docket No. RGT 9771

32. (Previously presented) The method of Claim 31, wherein the glucose solution is 5-10% glucose.
33. (Previously presented) The method of Claim 32, wherein the glucose solution is 8% glucose.
34. (Cancelled)
35. (Twice Amended) The method of Claim 23, further comprising one or more steps selected from the group consisting of receptor stimulation, toxin activation, ~~or~~ tissue injury ~~or and~~ cell injury.
36. (Cancelled)
37. (Previously presented) The method of Claim 23, wherein the ~~lentivirus is~~ protein is from a human immunodeficiency virus.
38. (Previously presented) The method of Claim 37, wherein the human immunodeficiency virus is replication-defective.
39. (Previously presented) The method of Claim 38, wherein the human immunodeficiency virus is integration-defective.
40. (Previously presented) The method of Claim 23, wherein the DNA is a plasmid.
41. (Previously presented) The method of Claim 23, wherein the cells are Langerhans cells.
42. (Amended) The method of Claim 29, wherein the complex comprises a 3:1 ratio molar equivalent of polyethylenimine ~~amine~~ nitrogen per ~~molar equivalent~~ of DNA phosphate.
43. (New) The method of Claim 25, wherein the derivative is a sugar-modified polyethylenimine.